<html><body><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation of technical requirements for registration of pharmaceuticals for human use    final concept <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2228">paper</a></span> q3c: impurities: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> dated and endorsed by the steering committee on 10 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1813">march</a></span> 1994  problem <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span>/objectives a general <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2440">policy</a></span> in limiting <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> (organic volatile impurities) qualitatively and quantitatively in drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> and excipient has not been defined globally. background/status quo at the second <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation in orlando in october 1993, the subject of impurities enjoyed substantial <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1476">interest</a></span> and debate. the expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group on quality is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> to create a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> on impurities and the pharmacopoeias have <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2077">standards</a></span> dealing with impurities. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicologists</a></span> also have participated on the subject of impurities, with regard to toxicity of process-related impurities. the issue remaining for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3470">resolution</a></span> with regard to impurities lines in the area of limits on low 
levels of organic volatile, e.g., <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residues</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>. so far, different limits are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span> or are being considered among the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> agencies and the pharmacopoeias. agreement on a single set of limits is highly desirable. the pharmacopoeias have begun studies for harmonisation of their approach for the control of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span>. however it is preferable that other <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1476">interested</a></span> parties participate in an effort to achieve agreement rather than the ich expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group and the pharmacopoeias reaching independent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decisions</a></span> which will have to be harmonised later through negotiation. impact the list of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3460">residual</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> to be limited and the limits tolerated for these <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4211">solvents</a></span> in each of 
the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3031"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3096">regions</a></span></a></span> differs (e.g. case by case <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> by the registration authorities, different proposals of usp, ph.<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054">eur</a></span>, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japanese</a></span> pharmacopoeia). this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2428">leads</a></span> to uncertainty and implies duplication of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">work</a></span> for industry. time frame given that the first prospectives have been studied within the pharmacopoeial discussion group it should be feasible to complete the topic and announce the results at the ich3 conference in november 1995. expert group the existing ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group on impurities composed of chemists and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4474">toxicologists</a></span> 
would be an appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6907">forum</a></span> with the addition of the experts of the pharmacopoeial bodies, i.e. the usp committee of revision, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/665"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/909"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054">european</a></span></a></span></a></span> pharmacopoeia commission and the committee on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japanese</a></span> pharmacopoeia.  -1- </body><html>